GlaxoSmithKline plc Q3 2025 Earnings Recap

GSK Q3 2025 October 29, 2025

GSK's Q3 2025 results reflect robust growth with total sales increasing by 8%, driven by strong performance in specialty medicines, and a significant upgrade in guidance for the year. The company also reported positive cash generation and progress in R&D, highlighting its commitment to innovation and sustainability.

Earnings Per Share Beat

$1.48 vs $1.26 est.

+17.5% surprise

Revenue Beat

8547000000 vs 8481214019 est.

+0.8% surprise

Market Reaction

1-Day +2.2%

5-Day +1.65%

30-Day +2.74%

Key Takeaways

Total sales reached GBP 8.5 billion in Q3, up 8% year-over-year, with specialty medicines growing 16%.
Core operating profit increased by 11%, and core EPS rose 14% to 55p.
GSK secured four FDA approvals this year, including for BLENREP, and expects to launch a low-carbon version of Ventolin in 2026.
Cash generation stood at GBP 6.3 billion year-to-date, supporting ongoing investments and a quarterly dividend of 16p.
Full-year specialty guidance has been upgraded from low teens to mid-teens percentage growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GSK on AllInvestView.

Previous Q2 2025